Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast Cancer
Nicholas C. Turner(Institute of Cancer Research), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Thomas J. Stout(Exelixis (United States)), Jennifer L. Schutzman(Cancer Research Institute), Guiyuan Lei(Cancer Research Institute), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Noopur Shankar(Cancer Research Institute), Patrapim Sunpaweravong(Prince of Songkla University), Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Seock‐Ah Im(Seoul National University), Sibylle Loibl(Goethe University Frankfurt), Cristina Saura(Vall d'Hebron Hospital Universitari), Dejan Juric(Massachusetts General Hospital), Katherine E. Hutchinson(Vanderbilt University), Huiping Li(Peking University), Chunyan Song(Zhengzhou Central Hospital), Qingyuan Zhang(Harbin Medical University), Eirini Thanopoulou(Cancer Research Institute), Peter Schmid(Queen Mary University of London), Sherene Loi(The University of Melbourne), Roland Leung(Cancer Research Institute), Kevin Kalinsky(Emory University)
Cited by 235
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k